1,126
Views
10
CrossRef citations to date
0
Altmetric
Non-Malignant Hematology

A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia

&
Pages 73-89 | Received 09 Nov 2016, Accepted 24 Feb 2017, Published online: 24 May 2017
 

ABSTRACT

Introduction: Pediatric immune thrombocytopenia (ITP) may be associated with significant burden on children and their parents/caregivers. Thrombopoietin (TPO) receptor agonists (RAs) have been used to treat adult patients with chronic ITP (cITP) for nearly a decade and following pediatric studies Eltrombopag has been recently approved for pediatric cITP in the United States and Europe. TPO-RA s may help reduce the risk of bleeding and the need for conventional ITP therapies.

Review: In this review, the clinical data demonstrating the efficacy and safety of TPO-RAs in pediatric ITP are evaluated, key recommendations regarding safe administration of eltrombopag are provided, and potential future directions in management of pediatric ITP are discussed.

Acknowledgments

All listed authors meet the criteria for authorship set forth by the International Committee of Medical Journal Editors.

Funding and declaration of interest

JDG reports personal fees and nonfinancial support from Novartis, GlaxoSmithKline, Amgen, and grant support from ITP Support Association (UK). ST has nothing to disclose.

Funding

Editorial support for the preparation of this manuscript was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.